Read More

Hillel's Tech Corner: NeuroSense: What ALS patients deserve

NeuroSense Therapeutics is a clinical stage drug development company offering ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.


Israeli biotech firm's ALS treatment shows safety of use in trials

The objective of this trial was to evaluate the safety of their treatment, with a secondary objective of the trial of estimating its preliminary efficacy.

Prof. Boaz Lerner of Ben-Gurion University uses a new platform for predicting ALS disease progressio

Investigational drug proven to prolong survival of ALS patients - study

The median overall survival for all CENTAUR study participants being administered AMX0035 was 6.5 months longer than the group originally randomized to placebo.

Israeli biotech firm's ALS treatment shows positive results in trials

"We are now focused on advancing strategic FDA regulatory processes that will necessitate the conduct of global multi-center clinical trials."

Israeli treatment could delay deadly effects of ALS – new study

AstroRx is a cell therapy product containing functional healthy astrocytes derived from human embryonic stem cells that aim to protect diseased motor neurons.

DINA AND Yitzi Hurwitz, pre-ALS. (Courtesy)

Rabbi suffering from ALS makes cross-country trip for son’s bar mitzvah

Rabbi Yitzi Hurwitz, 47, writes a weekly commentary on the Torah and a blog offering marriage advice.

Hadassah Ein Karem hospital in Jerusalem, Israel

ALS patient gets death wishes for planning to undergo treatment in Israel

"Some people enjoy insulting Paolo," said his brother to local media. "They look for any way to sabotage his actions."

DINA AND Yitzi Hurwitz, pre-ALS. (Courtesy)

Learning to focus with Dina Hurwitz

Dina was driving the older children from school in LA on a Friday when Yitzi phoned with the dread diagnosis. It was his 41st birthday.

Ben-Gurion University unveils AI platform for predicting ALS progression

There is currently neither a cure nor an effective treatment to halt or reverse the progressive disease.

NeuroSense Therapeutics CEO and co-founder Alon Ben-Noon

Meet the Israeli company optimistic about beating ALS

NeuroSense is planning to commence clinical trials later this year in the United States and Israel.

Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy